A non-interventional, mixed-methods, prospective cohort study to characterise the real-world implementation, roll out, safety and patient experience of the long-acting injectable HIV treatment regimen of 2-monthly cabotegravir and rilpivirine
Latest Information Update: 07 Mar 2024
At a glance
- Drugs Cabotegravir+rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms CORAL
- Sponsors ViiV Healthcare
Most Recent Events
- 17 Feb 2024 The Recruitment end date is 30 Apr 2026 ,as per ISRCTN: Current Controlled Trials record
- 09 Feb 2024 New trial record
- 07 Feb 2024 Status changed from not yet recruiting to recruiting.